Skip to main content
. 2021 Apr 29;18(1):91–97. doi: 10.1177/15563316211006710

Table 2.

Patient demographics stratified by clinical diagnosis of SpA.

SpA− (n = 26) SpA+ (n = 54) Overall a (n = 81)
Age (mean [SD]) 60 (8) 47 (19) 51 (17)
Male (%) 13 (50.0) 19 (35.2) 32 (39.5)
Inflammatory back pain (%) 9 (45.0) 41 (87.2) 51 (75.0)
Enthesitis (heel) (%) 1 (3.8) 8 (15.4) 9 (11.4)
Arthritis (%) 23 (88.5) 44 (86.3) 68 (87.2)
Uveitis (%) 2 (7.7) 5 (9.4) 7 (8.8)
Dactylitis (%) 1 (3.8) 2 (3.8) 3 (3.8)
Psoriasis (%) 9 (36.0) 19 (36.5) 28 (35.9)
IBD (%) 4 (15.4) 4 (7.7) 8 (10.1)
Response to NSAIDs (%) 11 (61.1) 26 (74.3) 37 (69.8)
Family history of SpA (%) 0 (0.0) 4 (8.2) 4 (5.3)
Family history of psoriatic arthritis (%) 3 (11.5) 9 (18.4) 12 (15.8)
Family history of rheumatoid arthritis (%) 2 (7.7) 4 (8.2) 6 (7.9)
Family history of gout (%) 1 (3.8) 1 (2.0) 2 (2.6)
Family history of scleroderma (%) 0 (0.0) 1 (2.0) 1 (1.3)
Family history of ankylosing spondylitis (%) 0 (0.0) 3 (6.1) 3 (3.9)
Family history of IBD (%) 1 (3.8) 4 (8.2) 6 (7.9)
Elevated CRP or ESR (%) 6 (26.1) 11 (21.2) 17 (22.4)
HLA-B27 (%) 1 (5.3) 11 (22.9) 12 (17.6)

SpA spondyloarthritis, IBD inflammatory bowel disease, NSAIDs nonsteroidal anti-inflammatory drugs, CRP C-reactive protein, ESR erythrocyte sedimentation rate, HLA human leukocyte antigen.

a

One case was indeterminate.